ABVC
ABVC BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.91
−0.86%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -53.0%
- Free cash flow
- -39.3%
- Operating cash flow
- -53.3%
Forward estimates
Based on analyst estimates
- Revenue
- +138.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -71.1%
- EBIT
- -52.0%
- Net income
- -61.3%
- EPS
- +7.1%
- Free cash flow
- -65.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026